Director declaration

ReNeuron Group plc

29 August 2023

 

ReNeuron Group plc

("ReNeuron" or the "Company")

Director declaration

ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosome Technologies, has been notified by Barbara Staehelin, Non-Executive Director, that QvQ AG, a company of which she was Non-Executive Chair until 31 August 2022, entered liquidation in July 2023, within 12 months of her ceasing to be a director of that company.

This announcement is made in accordance with AIM Rule 17 and Schedule Two, paragraph (g) of the AIM Rules for Companies.

Contacts:

ReNeuron		www.reneuron.com/investors
Iain Ross, Executive Chairman		Via Walbrook PR
John Hawkins, Chief Financial Officer
Allenby Capital Limited (Nominated Adviser and Broker)		[phone]
James Reeve/George Payne/Dan Dearden-Williams (Corporate Finance)
Stefano Aquilino/Kelly Gardiner (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations)		[phone] or [e-mail]
Paul McManus / Alice Woodings	[phone] / [phone]

About ReNeuron

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.

Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

 

END